These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11818641)

  • 61. Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
    Cox DA; Stone GW; Grines CL; Stuckey T; Cohen DJ; Tcheng JE; Garcia E; Guagliumi G; Iwaoka RS; Fahy M; Turco M; Lansky AJ; Griffin JJ; Mehran R;
    J Am Coll Cardiol; 2003 Sep; 42(6):971-7. PubMed ID: 13678914
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
    Rodriguez A; Rodríguez Alemparte M; Fernández Pereira C; Sampaolesi A; da Rocha Loures Bueno R; Vigo F; Obregón A; Palacios IF;
    Am J Med; 2005 Jul; 118(7):743-51. PubMed ID: 15989908
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction.
    Kim W; Jeong MH; Kim KH; Sohn IS; Hong YJ; Park HW; Kim JH; Ahn YK; Cho JG; Park JC; Cho DL; Kang JC
    J Am Coll Cardiol; 2006 Mar; 47(5):933-8. PubMed ID: 16516074
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
    Kim SS; Hong YJ; Jeong MH; Kim W; Kim HK; Ko JS; Lee MG; Sim DS; Park KH; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Song SJ; Cho DL; Kang JC
    Circ J; 2010 Mar; 74(3):442-8. PubMed ID: 20103970
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment synergy of silicon carbide-coated stenting and abciximab for complex coronary artery lesions: clinical results of a single-center study.
    van der Vleuten PA; Wijpkema JS; van den Heuvel AF; Bosma CA; Jessurun GA; Tio RA
    Ital Heart J; 2004 Sep; 5(9):663-6. PubMed ID: 15568593
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
    Khan MM; Ellis SG; Aguirre FV; Weisman HF; Wildermann NM; Califf RM; Topol EJ; Kleiman NS
    J Am Coll Cardiol; 1998 Jan; 31(1):31-6. PubMed ID: 9426014
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: in-hospital and six-month outcomes.
    Velianou JL; Strauss BH; Kreatsoulas C; Pericak D; Natarajan MK
    Catheter Cardiovasc Interv; 2000 Oct; 51(2):138-44. PubMed ID: 11025564
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Abciximab administration and outcome after intracoronary stent implantation.
    Hasdai D; Rihal CS; Bell MR; Berger PB; Grill DE; Garratt KN; Holmes DR
    Am J Cardiol; 1998 Sep; 82(6):705-9. PubMed ID: 9761077
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ; Foster RH
    Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
    Schulz S; Mehilli J; Ndrepepa G; Dotzer F; Dommasch M; Kufner S; Birkmeier KA; Tiroch K; Byrne RA; Schömig A; Kastrati A
    Clin Res Cardiol; 2011 Aug; 100(8):691-9. PubMed ID: 21384174
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Emergency coronary artery bypass graft surgery in abciximab-treated patients.
    Lemmer JH; Metzdorff MT; Krause AH; Martin MA; Okies JE; Hill JG
    Ann Thorac Surg; 2000 Jan; 69(1):90-5. PubMed ID: 10654493
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock.
    Giri S; Mitchel J; Azar RR; Kiernan FJ; Fram DB; McKay RG; Mennett R; Clive J; Hirst JA
    Am J Cardiol; 2002 Jan; 89(2):126-31. PubMed ID: 11792329
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
    Oemrawsingh PV; Schalij MJ; Udayachalerm W; van der Wall EE; Bruschke AV
    Cathet Cardiovasc Diagn; 1998 Jun; 44(2):131-7. PubMed ID: 9637432
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
    Hong MK; Mintz GS; Lee CW; Kim YH; Lee SW; Song JM; Han KH; Kang DH; Song JK; Kim JJ; Park SW; Park SJ
    Circulation; 2004 Feb; 109(7):881-6. PubMed ID: 14967732
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
    Kandzari DE; Tcheng JE; Cohen DJ; Bakhai A; Grines CL; Cox DA; Effron M; Stuckey T; Griffin JJ; Turco M; Carroll JD; Fahy M; Mehran R; Stone GW;
    Am J Cardiol; 2003 Oct; 92(7):779-84. PubMed ID: 14516875
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
    Bhatt DL; Lincoff AM; Califf RM; Simoons ML; Tcheng JE; Brener SJ; Wolski KE; Topol EJ
    Am J Cardiol; 2000 May; 85(9):1060-4. PubMed ID: 10781752
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.
    Antoniucci D; Rodriguez A; Hempel A; Valenti R; Migliorini A; Vigo F; Parodi G; Fernandez-Pereira C; Moschi G; Bartorelli A; Santoro GM; Bolognese L; Colombo A
    J Am Coll Cardiol; 2003 Dec; 42(11):1879-85. PubMed ID: 14662245
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Abciximab. An updated review of its use in ischaemic heart disease.
    Foster RH; Wiseman LR
    Drugs; 1998 Oct; 56(4):629-65. PubMed ID: 9806109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.